title: Treatment of acromegaly in the era of personalized and predictive medicine.
abstract: Acromegaly is a chronic disorder usually diagnosed late in the disease evolution. Such delayed diagnosis, together with the inability to achieve the treatment goals of normalizing biochemical disease markers and controlling tumour mass may result in substantial morbidity and mortality. Somatostatin analogues (SSA) are accepted as first-line medical therapy or as second-line therapy in patients undergoing unsuccessful surgery and are considered a cornerstone in the treatment of acromegaly. However, because a high percentage of patients experience SSA medical treatment failure, the identification of biomarkers associated with a successful or unsuccessful response to all classes of medical therapy would help in the choice of treatment and potentially allow for a quicker normalization of biochemical parameters. The current treatment algorithms for acromegaly are based upon a "trial-and-error" approach with additional treatment options provided when disease is not controlled. In many other diseases, therapeutic algorithms have been evolving towards personalized treatment with the medication that best matches individual disease characteristics, using biomarkers that identify therapeutic response. Additionally, a personalized approach to complementary treatment of comorbidities present in the acromegalic patient is also required. This review will discuss the development of a potential treatment algorithm for acromegaly addressing the biochemical control of the disease as well of its associated comorbidities, under a personalized approach based upon markers of prognostic and predictive significance, such as tumour size, MRI adenoma signal, GH value after acute octreotide test, granular adenoma pattern, Ki-67, somatostatin receptor phenotype, aryl hydrocarbon-interacting protein expression, gsp mutations, RAF kinase activity, E-cadherin and beta-arrestin-1.
authors: Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors: Manuel
authors: M
authors: Puig Domingo
mesh_terms: D000236:Adenoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D019390:Arrestins / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D009154:Mutation; D019635:Neurosurgical Procedures; D015282:Octreotide / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D057285:Precision Medicine; D011379:Prognosis; D043562:Receptors, G-Protein-Coupled / Q000235:genetics; D017481:Receptors, Somatostatin / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure; D016896:Treatment Outcome; D047368:Tumor Burden; D000071559:beta-Arrestin 1; D000071557:beta-Arrestins; D048490:raf Kinases / Q000378:metabolism
chemical_list: C000605253:ARRB1 protein, human; D018931:Antineoplastic Agents, Hormonal; D019390:Arrestins; D015820:Cadherins; D047908:Intracellular Signaling Peptides and Proteins; D019394:Ki-67 Antigen; D010456:Peptides, Cyclic; D043562:Receptors, G-Protein-Coupled; D017481:Receptors, Somatostatin; C103265:aryl hydrocarbon receptor-interacting protein; D000071559:beta-Arrestin 1; D000071557:beta-Arrestins; C060347:lanreotide; D013004:Somatostatin; D048490:raf Kinases; D015282:Octreotide